- Home
- ABOS vs CFBK Comparison
ABOS vs CFBK Comparison
Compare ABOS & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABOS | CFBK |
|---|---|---|
| Founded | 1996 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.7M | 184.4M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ABOS | CFBK |
|---|---|---|
| Price | $2.59 | $28.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $7.75 | ★ $29.00 |
| AVG Volume (30 Days) | ★ 473.4K | 42.8K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.32% |
| EPS Growth | N/A | ★ 30.58 |
| EPS | N/A | ★ 2.69 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $32.28 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $19.22 |
| 52 Week High | $3.60 | $34.34 |
Technical Indicators
Market Signals| Indicator | ABOS | CFBK |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 41.68 |
| Support Level | $1.21 | $23.79 |
| Resistance Level | $3.05 | $29.95 |
| Average True Range (ATR) | 0.26 | 0.83 |
| MACD | -0.11 | -0.18 |
| Stochastic Oscillator | 5.56 | 35.26 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.